DDX10 overexpression predicts worse prognosis in osteosarcoma and its deletion prohibits cell activities modulated by MAPK pathway
Authors:
Open Access
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 510 (4) , 525-529
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in OsteosarcomaPLOS ONE, 2012
- Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AMLBlood, 2011
- Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungsInternational Journal of Cancer, 2009
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- Oncogenic role of DDX3 in breast cancer biogenesisOncogene, 2008
- Osteosarcoma, Chondrosarcoma, and Ewing's SarcomaClinical Orthopaedics and Related Research, 2007
- Markers of angiogenesis and clinical features in patients with sarcomaCancer, 2007
- DEAD-box proteins: the driving forces behind RNA metabolismNature Reviews Molecular Cell Biology, 2004
- Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group ProtocolsJournal of Clinical Oncology, 2003
- A Human Gene (DDX10) Encoding a Putative DEAD-Box RNA Helicase at 11q22–q23Genomics, 1996